Hepatitis B Virus (HBV)
10
2
2
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
30%
3 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (10)
Combating Related Epidemics in HCV
Rapid HIV, Hep C, and Syphilis Screening in a Rural Street Medicine Clinic
Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors
Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study
The Impact of Treatment for Chronic Hepatitis B Virus on Non-clinical Harms
Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France
Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) Combined With Nucleoside (Acid) Analogues in Chronic Hepatitis B Patients
Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) in Chronic Hepatitis B Patients
Sonoelastography: Ultrasound Method to Measure Liver Fibrosis
Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection